Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

Fig. 1

Effect of MEK162/BKM120 combination therapy on human non-small cell lung carcinoma (NSCLC) H1975, H460, and A549 cell viability. H1975 (A), H460 (B), and A549 (C) cells were treated with MEK162 (MEK inhibitor) (0–3 µM) or BKM120 (PI3K inhibitor) (0–15 µM) alone or their combination for 48 h, and cell viability was evaluated by MTT assay. Data are the percentages of viable cells compared with the untreated controls (0.05% DMSO) and are represented as means ± standard deviation (SD) from three independent experiments. *P < 0.05 vs. 1 μM MEK162; #P < 0.05 vs. 5 μM BKM120; ▲P < 0.05 vs. H1975; &P < 0.05 vs. H460

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us